JP2009515553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515553A5 JP2009515553A5 JP2008541268A JP2008541268A JP2009515553A5 JP 2009515553 A5 JP2009515553 A5 JP 2009515553A5 JP 2008541268 A JP2008541268 A JP 2008541268A JP 2008541268 A JP2008541268 A JP 2008541268A JP 2009515553 A5 JP2009515553 A5 JP 2009515553A5
- Authority
- JP
- Japan
- Prior art keywords
- test kit
- cells
- solution
- vegfr
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 239000000523 sample Substances 0.000 claims 7
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 6
- 108091008605 VEGF receptors Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002934 lysing effect Effects 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000001235 sensitizing effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 1
- 230000003100 immobilizing effect Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73585405P | 2005-11-14 | 2005-11-14 | |
| PCT/US2006/044117 WO2007059094A2 (en) | 2005-11-14 | 2006-11-14 | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515553A JP2009515553A (ja) | 2009-04-16 |
| JP2009515553A5 true JP2009515553A5 (enExample) | 2009-12-10 |
Family
ID=37814675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008541268A Pending JP2009515553A (ja) | 2005-11-14 | 2006-11-14 | 癌の予知および予後と、癌治療のモニタリング |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20070178494A1 (enExample) |
| EP (1) | EP1963849A2 (enExample) |
| JP (1) | JP2009515553A (enExample) |
| KR (1) | KR20080073745A (enExample) |
| CN (1) | CN101454668A (enExample) |
| AU (1) | AU2006315592A1 (enExample) |
| BR (1) | BRPI0618597A2 (enExample) |
| CA (1) | CA2629860A1 (enExample) |
| MX (1) | MX2008006239A (enExample) |
| RU (1) | RU2008123406A (enExample) |
| WO (1) | WO2007059094A2 (enExample) |
| ZA (1) | ZA200804509B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| US7838541B2 (en) | 2002-02-11 | 2010-11-23 | Bayer Healthcare, Llc | Aryl ureas with angiogenesis inhibiting activity |
| UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
| WO2004113274A2 (en) | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| RS52625B (sr) | 2003-07-23 | 2013-06-28 | Bayer Healthcare Llc | Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti |
| KR101335932B1 (ko) * | 2005-03-07 | 2013-12-04 | 바이엘 헬스케어 엘엘씨 | 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물 |
| CN101506351A (zh) * | 2005-10-21 | 2009-08-12 | 拜尔健康护理有限责任公司 | 用于癌症预测和预后及监测癌症治疗的方法 |
| WO2007056012A2 (en) * | 2005-11-02 | 2007-05-18 | Bayer Healthcare Llc | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
| WO2008033782A2 (en) * | 2006-09-12 | 2008-03-20 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of lung cancer using pdgfra, kit or kdr gene as genetic marker |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| WO2009094383A2 (en) * | 2008-01-25 | 2009-07-30 | Mayo Foundation For Medical Education And Research | Quantitation of lobular involution for breast cancer risk prediction |
| GB0814722D0 (en) * | 2008-08-12 | 2008-09-17 | Ge Healthcare Ltd | Treatment monitoring |
| EP2156834A1 (en) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
| JP5439494B2 (ja) * | 2008-10-21 | 2014-03-12 | バイエル ヘルスケア エルエルシー | 肝細胞癌と関連するシグネチャ遺伝子の同定 |
| BR112012007762A2 (pt) * | 2009-10-07 | 2021-11-16 | Koninklijke Philips Electronics Nv | Método de avaliação do nível de toxicidade de um paciente que se submete a um protocolo de tratamento de câncer, produto de programa de computador, sistema (200) para avaliar o nível de toxicidade de um paciente que se submete a um protocolo de tratamento de câncer |
| CN102053150B (zh) * | 2009-10-30 | 2013-07-17 | 上海交通大学医学院附属瑞金医院 | 一种人成骨肉瘤干细胞相关抗原标记物及其应用 |
| KR20130091750A (ko) * | 2010-07-19 | 2013-08-19 | 에프. 호프만-라 로슈 아게 | 유방암의 치료를 위한 베바시주맙 병용 치료법을 위한 혈장 생체마커 |
| EP2601528B1 (en) * | 2010-08-02 | 2015-10-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor |
| US9315869B2 (en) | 2010-12-13 | 2016-04-19 | Samsung Life Public Welfare Foundation | Marker for predicting gastric cancer prognosis and method for predicting gastric cancer prognosis using the same |
| EP2663650B1 (en) * | 2011-01-11 | 2016-11-09 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting the outcome of a cancer in a patient by analysing gene expression |
| WO2013173384A1 (en) * | 2012-05-16 | 2013-11-21 | Dale Wong | Method and system for sorting biological samples |
| US10041125B2 (en) * | 2013-03-15 | 2018-08-07 | Janssen Pharmaceutica Nv | Assay for predictive biomarkers |
| EP2989466B1 (en) * | 2013-04-25 | 2018-10-31 | CBS Bioscience, Co., Ltd | Analytical method for increasing susceptibility of molecular targeted therapy in hepatocellular carcinoma |
| RU2546035C1 (ru) * | 2014-04-15 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ прогнозирования развития метастазов у больных меланомой кожи |
| RU2643761C1 (ru) * | 2017-08-10 | 2018-02-05 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ расчета прогноза раннего прогрессирования меланомы кожи |
| WO2019074920A1 (en) * | 2017-10-10 | 2019-04-18 | Oncocyte Corporation | METHODS AND COMPOSITIONS FOR THE DETECTION AND DIAGNOSIS OF BREAST CANCER |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635421B1 (en) * | 1997-12-09 | 2003-10-21 | Children's Medical Center Corporation | Neuropilins and use thereof in methods for diagnosis and prognosis of cancer |
| US20030232400A1 (en) * | 2002-12-20 | 2003-12-18 | Susan Radka | Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome |
| WO2005009367A2 (en) * | 2003-07-17 | 2005-02-03 | Ambit Biosciences Corporation | Treatment of diseases with kinase inhibitors |
| MXPA06010667A (es) * | 2004-03-19 | 2007-07-04 | Penn State Res Found | Metodos combinatorios y composiciones para el tratamiento de melanoma. |
-
2006
- 2006-11-14 KR KR1020087014220A patent/KR20080073745A/ko not_active Withdrawn
- 2006-11-14 CA CA002629860A patent/CA2629860A1/en not_active Abandoned
- 2006-11-14 EP EP06837519A patent/EP1963849A2/en not_active Withdrawn
- 2006-11-14 CN CNA2006800505936A patent/CN101454668A/zh active Pending
- 2006-11-14 BR BRPI0618597-5A patent/BRPI0618597A2/pt not_active IP Right Cessation
- 2006-11-14 JP JP2008541268A patent/JP2009515553A/ja active Pending
- 2006-11-14 RU RU2008123406/15A patent/RU2008123406A/ru not_active Application Discontinuation
- 2006-11-14 AU AU2006315592A patent/AU2006315592A1/en not_active Abandoned
- 2006-11-14 MX MX2008006239A patent/MX2008006239A/es not_active Application Discontinuation
- 2006-11-14 US US11/598,824 patent/US20070178494A1/en not_active Abandoned
- 2006-11-14 WO PCT/US2006/044117 patent/WO2007059094A2/en not_active Ceased
-
2008
- 2008-05-23 ZA ZA200804509A patent/ZA200804509B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515553A5 (enExample) | ||
| Wang et al. | Detection of SARS-CoV-2 and its mutated variants via CRISPR-Cas13-based transcription amplification | |
| Le et al. | Dual recognition element lateral flow assay toward multiplex strain specific influenza virus detection | |
| Zhou et al. | Long non-coding RNA ANRIL regulates inflammatory responses as a novel component of NF-κB pathway | |
| ES2540108T3 (es) | Marcadores en la orina para la detección del cáncer de vejiga | |
| Tainsky | Genomic and proteomic biomarkers for cancer: a multitude of opportunities | |
| JP2007525661A5 (enExample) | ||
| EP2376656A2 (en) | Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis | |
| JP2011528903A5 (enExample) | ||
| JP2012526554A5 (enExample) | ||
| KR20080114689A (ko) | 증가된 ｂｃｌ-2에 의한 암의 발견 | |
| JP2010536372A5 (enExample) | ||
| JP2019500582A5 (enExample) | ||
| JP2015500478A (ja) | ヌクレオソームアダクト検出法 | |
| JP2013178260A5 (enExample) | ||
| DE602005011008D1 (de) | Verwendung der Gene Kir2.3 und DRD2 als molekulare Marker zur Diagnose von Schizophrenie | |
| JP2010521655A5 (enExample) | ||
| US12195795B2 (en) | Synthetic strands for nucleic acid sequencing and related methods and systems | |
| JP2013508719A5 (enExample) | ||
| Saber et al. | Lack of acute phase response in the livers of mice exposed to diesel exhaust particles or carbon black by inhalation | |
| EP4237850A1 (en) | Improved assays to quantify chromatin targets using antibody-targeted enzyme digestion | |
| JP2022515221A (ja) | クロマチンマッピングアッセイ用のｄｎａバーコード化ヌクレオソーム | |
| Pereira et al. | Enlarging the toolbox against antimicrobial resistance: aptamers and CRISPR-Cas | |
| JP2011519030A5 (enExample) | ||
| US20240318255A1 (en) | Transcription factor binding site analysis of nucleosome depleted circulating cell free chromatin fragments |